Tournament: Jack Howe | Round: 2 | Opponent: CL | Judge: Lukas Krause
1NC – Off
Biotech industry strong now.
Cancherini et al. 4/30 (Laura, Engagement Manager @ McKinsey and Company, Joseph Lydon, Associate Partner @ McKinsey and Company, Jorge Santos Da Silva, Senior Partner at McKinsey and Company, and Alexandra Zemp, Partner at McKinsey and Company), "What’s ahead for biotech: Another wave or low tide?", McKinsey and Company, 4-30-2021, https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/whats-ahead-for-biotech-another-wave-or-low-tide~~ TDI
As the pandemic spread across the globe in early 2020, biotech leaders were initially
AND
as multi-omics tailored diets) to a multitude of health applications.
IP protections are key to innovation – recouping startup costs and high risk of failure
Grabowski et al 15 (Henry, Professor of Economics, member of the faculty for the Health Sector Management Program, and Director of the Program in Pharmaceuticals and Health Economics at Duke University) "The Roles of Patents and Research And Development Incentives In Biopharmaceutical Innovation," Health Affairs, 2/2015 JL
The essential rationale for patent protection for biopharmaceuticals is that long-term benefits in
AND
protection plays a key role in funding and partnership opportunities for such firms.
IP enables critical information sharing
Simon 6/25 (Brenda, professor at California Western School of Law, research interests focus on how technological developments affect intellectual property and information law, former teaching fellow for the Law, Science and Technology LL.M. Program at Stanford Law School, and a research fellow in the Stanford Center for Law and the Biosciences, JD from UC Berkeley School of Law) "Patents, Information, and Innovation," Brooklyn Law Review, 6/25/2020 JL
Patents play numerous roles in encouraging the exchange of information during the investment-seeking
AND
protection would be available for some medical devices have also raised concerns.229
Biopharmaceutical innovation is key to prevent future pandemics and bioterror.
Marjanovic and Feijao 20 (Sonja Marjanovic, Ph.D., Judge Business School, University of Cambridge. Carolina Feijao, Ph.D. in biochemistry, University of Cambridge; M.Sc. in quantitative biology, Imperial College London; B.Sc. in biology, University of Lisbon.) "How to Best Enable Pharma Innovation Beyond the COVID-19 Crisis," RAND Corporation, 05-2020, https://www.rand.org/pubs/perspectives/PEA407-1.html~~ TDI
As key actors in the healthcare innovation landscape, pharmaceutical and life sciences companies have